Abstract:e15514 Background: Trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein in epithelial cells, is implicated in malignant progression, notably in breast cancer therapy. However, the clinicopathologic aspects of TROP2 in colorectal cancer (CRC) are unclear. This study aims to explore the association between TROP2 expression and clinicopathological features in CRC and investigate the inhibitory effects of the anti-TROP2 antibody-SN-38 conjugate (ADC-TROP2) on colon cancer cells. Methods: A retrospective analysis of 1296 CRC patients who underwent colorectomy at Renji Hospital, Shanghai Jiaotong University School of Medicine, was conducted. Immunohistochemistry determined the expressions of TROP2, HER2, and PD-L1 in colon cancer tissues. Statistical analyses, including the chi-square test and Cox proportional hazards model, assessed associations. Sacituzumab Govitecan (ADC-TROP2 drug) cytotoxicity on human cancer cells was determined using the MTT method. Results: TROP2 was predominantly expressed at the cell membrane of cancer tissues, with 50% of cases TROP2-positive. The overexpression of TROP2 (staining extension 2+ or 3+) were found in 356 (27.5%) cases. The clinicopathological features of all 1296 patients based on the TROP2 expression in their cancer cells were summarized in Table 1. Compared to TROP2 negativity expression, the high TROP2 expression was significantly associated with the advantaged tumor stage (III/IV, P = 0.022), high tumor invasion depth (T3/T4, P = 0.002), lymph node metastasis (N1/N2, p = 0.026), HER-2 expression (2+/3+, p = 0.013) ,PD-L1 CPS (CPS≤5,P = 0.007). Sacituzumab Govitecan exhibited stronger inhibition in TROP2-positive human CRC cells in TROP2-negative CRC cells compared to TROP2-negative cells and the control SN-38 agent. Conclusions: TROP2 expression positive in 50% of CRC cases is associated with with advantaged tumor stage, high tumor invasion depth, lymph node metastasis. Sacituzumab Govitecan demonstrates potent targeting of TROP2-positive CRC cells, suggesting TROP2 as a potential biomarker for clinical prognosis and therapeutic targeting in colon cancer. [Table: see text]

TROP 2 is associated with the recurrence of patients with non-muscle invasive bladder cancer

Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway

Trophoblast Cell-Surface Antigen 2 is a Biomarker and Potential Therapeutic Target in Human Colon Cancer.

Prognostic Value of TROP2 in Human Nasopharyngeal Carcinoma.

TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis

Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapy

Overexpression of TROP2 Promotes Proliferation and Invasion of Ovarian Cancer Cells

TROP2 Correlates with Microvessel Density and Poor Prognosis in Hilar Cholangiocarcinoma

Expression and significance of Trop-2 in non-small cell lung cancer

Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation

Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma.

TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection

TROP2 As Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer

High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker

The Impact of Trophoblast Cell-Surface Antigen 2 Expression on the Survival of Patients with Gastrointestinal Tumors: A Systematic Review

Trop-2 expression and the tumor immune microenvironment in cervical cancer

TROP2 Promotes the Proliferation and Metastasis of Glioblastoma Cells by Activating the JAK2/STAT3 Signaling Pathway

Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues

Primary Study of Expression of TROP-2 in Human Pulmonary Adenocarcinoma and Cell Lines